Table 3: Comparisons of demographic, clinical, and laboratory features, vascular risk factors, and medications between the 7 PAPS patients with seizures after APS diagnosis and those without seizures ( 𝑛 = 7 9 ).

PAPS with epileptic seizures after APS onset 𝑛 = 7 PAPS without epileptic seizures 𝑛 = 7 9 𝑃 value

Age, years 4 2 ± 1 0 . 3 4 0 . 1 ± 1 1 . 2 0.670
White race, 𝑛 (%)5 (71.4)65 (82.3)0.610
Female gender, 𝑛 (%)5 (71.4)650.610
Body mass index, kg/m2 2 7 . 5 ± 2 . 9 2 8 . 0 ± 7 . 5 0.866
Arterial events, 𝑛 (%)5 (71.4)38 (48.1)0.433
Venous events, 𝑛 (%)2 (28.6)49 (62.0)0.115
Obstetric events, 𝑛 (%)2 (28.6)31 (39.2)0.703
Thrombocytopenia, 𝑛 (%)2 (28.6)19 (24.1)1.000
Livedo reticularis, 𝑛 (%)4 (57.1)24 (30.4)0.208
Stroke, 𝑛 (%)5 (71.4)24 (30.4)0.041
Sneddon’s syndrome, 𝑛 (%)3 (42.9)12 (15.2)0.098
Pulmonary thromboembolism, 𝑛 (%)1 (14.3)19 (24.1)0.678
Deep venous thrombosis, 𝑛 (%)2 (28.6)40 (50.6)0.434
Angina, 𝑛 (%)07 (8.9)1.000
Acute myocardial infarction, 𝑛 (%)01 (1.3)1.000
Sedentarism, 𝑛 (%)5 (71.4)50 (63.3)1.000
Disease duration, months 9 2 . 6 ± 1 0 1 . 9 9 4 . 6 ± 6 4 . 3 0.470
Metabolic syndrome, 𝑛 (%)017 (21.5)0.336
Diabetes, 𝑛 (%)06 (7.6)1.000
Systemic hypertension, 𝑛 (%)3 (42.9)37 (46.8)1.000
Previous history of smoking, 𝑛 (%)5 (71.4)28 (35.4)0.101
Current smoking, 𝑛 (%)3 (42.9)8 (10.1)0.042
Alcoholism, 𝑛 (%)1 (14.3)01.000
Heparin use, 𝑛 (%)4 (57.1)37 (46.8)1.000
Current chloroquine use, 𝑛 (%)2 (28.6)37 (46.8)0.448
Statin use, 𝑛 (%)020 (25.3)0.193
IgG anticardiolipin levels, GPL 5 7 . 4 ± 5 0 . 4 4 0 . 0 ± 4 6 . 3 0.347
IgG anticardiolipin, 𝑛 (%)5 (71.4)44 (55.7)1.000
IgM anticardiolipin levels, MPL 1 9 . 9 ± 2 1 . 6 2 9 . 9 ± 4 0 . 2 0.518
IgM anticardiolipin, 𝑛 (%)4 (57.1)40 (50.6)1.000
Lupus anticoagulant, 𝑛 (%)5 (71.4)60 (75.9)1.000

Data expressed as mean ± standard deviation or percentage; PAPS: primary antiphospholipid syndrome; 𝑛 = number of patients; SD = standard deviation.